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background: Real-life clinical experience of hypertrophic cardiomyopathy (HCM) in community hospitals is lacking. We aim to report our 
contemporary experience of a newly established HCM center where patients (pts) are referred for comprehensive evaluation.
methods/results: From 7/2010 to 9/2013, 228 pts were referred. 187 (82%) were phenotype positive (P+) for HCM, with 5% involving apex. 
Mean maximal left ventricular thickness was 2.2 ± 1.4 cm, with >2.5 cm thickness seen in 20%. Of 41 phenotype-negative pts, 44% were sarcomere 
gene positive (G+), 37% were gene negative (G-), and 20% were HCM phenocopies (2 Danon, 3 Fabry, 2 amyloid and 1 hypertension). Obstructive 
HCM was present in 70%. P+ characteristics included: mean age 49 ± 19 years, males 54%, whites 74%, hypertension 62%, sleep apnea 62%, NYHA 
III/IV symptoms 23% and >grade 1 diastolic dysfunction 65%. Mean global longitudinal strain was -15.9 ± 4. At least 1 sudden death risk factor 
was present in 72%, and 23% received implantable defibrillator. 43% had magnetic resonance imaging; 58% of those had delayed enhancement. 
Management included beta blockers in 81%, calcium channel blockers in 40%, angiotensin blockers in 27% and disopyramide in 38%. Septal 
reduction included ablation in 26% and myectomy in 13%. Genetic testing was performed in 63%. Significant differences among G+ vs. G- are shown 
in the table.
conclusion: We present the largest, most contemporary, single-center community hospital HCM experience conforming to the latest guidelines.
